Drugs / ENZ215
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05405725 | Jul 2022 → Jul 2024 | postmenopausal osteoporosis | Enzene Biosciences Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENZ215 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05405725 ↗ |
| Known as | Enzene Denosumab | “Enzene Denosumab (ENZ215)” NCT05405725 ↗ |